{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Normal+Saline+IV+Administration", "query": { "intervention": "Normal Saline IV Administration" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 544, "total_pages": 55, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Normal+Saline+IV+Administration&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-17T22:24:30.056Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05669846", "title": "Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Healthy Donor Fecal Microbiota Transplant (hdFMT)", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Diwakar Davar", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2025-01-08", "completion_date": "2036-12-31", "has_results": false, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-09-17T22:24:30.056Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05669846" }, { "nct_id": "NCT03885596", "title": "Open-Label CA-008 (Vocacapsaicin) in Bunionectomy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pain" ], "interventions": [ { "name": "CA-008", "type": "DRUG" }, { "name": "Ketorolac", "type": "DRUG" }, { "name": "Acetaminophen IV", "type": "DRUG" }, { "name": "Fentanyl", "type": "DRUG" }, { "name": "Bupivacaine Hydrochloride", "type": "DRUG" }, { "name": "Lidocaine HCl", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Acetaminophen Oral", "type": "DRUG" }, { "name": "Lidocaine Hydrochloride", "type": "DRUG" }, { "name": "Exparel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Concentric Analgesics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 36, "start_date": "2019-03-25", "completion_date": "2019-10-22", "has_results": true, "last_update_posted_date": "2021-10-27", "last_synced_at": "2026-09-17T22:24:30.056Z", "location_count": 1, "location_summary": "Pasadena, California", "locations": [ { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03885596" }, { "nct_id": "NCT05717062", "title": "Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Snakebite", "Envenoming, Snake" ], "interventions": [ { "name": "Varespladib intravenous form", "type": "DRUG" }, { "name": "varespladib-methyl- oral form", "type": "DRUG" }, { "name": "Placebo intravenous form", "type": "DRUG" }, { "name": "Placebo - oral form", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ophirex, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2023-05-30", "completion_date": "2025-02-24", "has_results": false, "last_update_posted_date": "2025-06-27", "last_synced_at": "2026-09-17T22:24:30.056Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Palm Springs, California + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Palm Springs", "state": "California" }, { "city": "Rosamond", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05717062" }, { "nct_id": "NCT07472491", "title": "A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Known or Highly Suspected Central Nervous System (CNS) Lesion", "Known or Highly Suspected Body (Excluding CNS) Lesion" ], "interventions": [ { "name": "Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL", "type": "DRUG" }, { "name": "MRI Scan", "type": "DIAGNOSTIC_TEST" }, { "name": "Gadobutrol", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "GE Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 640, "start_date": "2026-04-01", "completion_date": "2027-11-30", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-09-17T22:24:30.056Z", "location_count": 2, "location_summary": "Rochester, Minnesota • The Woodlands, Texas", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "The Woodlands", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07472491" }, { "nct_id": "NCT03525678", "title": "A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Belantamab mafodotin frozen liquid", "type": "DRUG" }, { "name": "Belantamab mafodotin lyophilized powder", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 221, "start_date": "2018-06-18", "completion_date": "2024-09-12", "has_results": true, "last_update_posted_date": "2025-09-03", "last_synced_at": "2026-09-17T22:24:30.056Z", "location_count": 21, "location_summary": "New Haven, Connecticut • Atlanta, Georgia • Chicago, Illinois + 15 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03525678" }, { "nct_id": "NCT01147341", "title": "Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Cimzia", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Michael Schiff, MD", "sponsor_class": "INDIV", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 37, "start_date": "2010-07", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2014-06-09", "last_synced_at": "2026-09-17T22:24:30.056Z", "location_count": 12, "location_summary": "Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 9 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01147341" }, { "nct_id": "NCT00809146", "title": "Paramedic Treatment of Prolonged Seizures by Intramuscular Versus Intravenous Anticonvulsant Medications", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Status Epilepticus" ], "interventions": [ { "name": "Intramuscular route of active treatment", "type": "DRUG" }, { "name": "Intravenous route of active treatment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Robert Silbergleit", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1023, "start_date": "2009-06", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2016-06-17", "last_synced_at": "2026-09-17T22:24:30.056Z", "location_count": 17, "location_summary": "Tucson, Arizona • Palo Alto, California • San Francisco, California + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT00809146" }, { "nct_id": "NCT06418022", "title": "Evaluating Fluid Responsiveness in ICU Patients Using VTI and Trendelenburg Positioning", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Shock", "Fluid Overload", "Cardiac Output, Low" ], "interventions": [ { "name": "Trendelenburg positioning VTI", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Lenox Hill Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2024-04-01", "completion_date": "2025-08-01", "has_results": false, "last_update_posted_date": "2024-05-16", "last_synced_at": "2026-09-17T22:24:30.056Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06418022" }, { "nct_id": "NCT05952804", "title": "IVIG for Infection Prevention After CAR-T-Cell Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "Immune Globulin Infusion (Human), 10% Solution", "type": "BIOLOGICAL" }, { "name": "Anti-CD19 CAR T Cells Preparation", "type": "BIOLOGICAL" }, { "name": "Saline", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Electronic Health Record Review", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2024-06-10", "completion_date": "2028-07-31", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-09-17T22:24:30.056Z", "location_count": 7, "location_summary": "Duarte, California • Miami, Florida • Tampa, Florida + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05952804" }, { "nct_id": "NCT03737643", "title": "Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Ovarian Cancer" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Placebo olaparib", "type": "DRUG" }, { "name": "Durvalumab placebo", "type": "DRUG" }, { "name": "Carboplatin+Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "FEMALE", "summary": "18 Years to 130 Years · Female only" }, "enrollment_count": 1407, "start_date": "2019-01-04", "completion_date": "2026-12-23", "has_results": true, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-09-17T22:24:30.056Z", "location_count": 26, "location_summary": "Foothill Ranch, California • Los Angeles, California • Orange, California + 22 more", "locations": [ { "city": "Foothill Ranch", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03737643" } ] }